Cambridge healthcare company, ImmunoBiology Limited (“ImmBio”) has appointed biotech entrepreneur Alan Goodman as its Chairman.
Alan Goodman is a chartered management accountant with over 20 years experience in the biotechnology and healthcare industries. He has founded or co-founded a number of biopharmaceutical companies including Peptide Therapeutics (now known as Acambis) and CeNeS Pharmaceuticals. Alan is founder and Chief Executive of Avlar BioVentures Ltd and will continue to serve as a non-executive Director of the company.
Alan joins Graham Clarke, CEO, Dr Camilo Colaco, Managing Director, and Dr Chris Bailey, Development Director.
ImmBio was founded in May 1999 by Dr Colaco and has raised funds from three venture capital sources, Generics Asset Management, British Smaller Technology Companies VCT 2 and Oxford Technology 3VCT. In addition ImmBio has been the recipient of both SMART feasibility and SMART Development awards by the DTI.
Commenting on the appointment, ImmBio Managing Director, Dr Camilo Colaco comments: “I am delighted to welcome Alan Goodman to the ImmBio Board. His extensive experience in the biotechnology sector and particularly in the vaccine industry will guide us though our transition from start-up phase into pre-clinical development later this year”. “Though most people know Alan as a seasoned biotechnology entrepreneur, he has a long history in the vaccine industry originally with the purchase of Evans Vaccines and Wellcome Biotech for Medeva and more recently the purchase of Oravax for Acambis”, he added.
“The recent SARS epidemic and influenza outbreak in China serve as a reminder that infectious diseases represent the most significant threat to global healthcare and ImmunoBiology has the technology to address the significant need for new and better vaccines in the healthcare industry globally” commented Mr Goodman.
|
